Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) saw a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 45,300 shares, a decline of 11.5% from the March 15th total of 51,200 shares. Approximately 0.9% of the shares of the company are short sold. Based on an average trading volume of 54,600 shares, the days-to-cover ratio is currently 0.8 days.
Alzamend Neuro Stock Down 12.8 %
ALZN stock traded down $0.11 during trading on Monday, reaching $0.74. 114,685 shares of the company’s stock were exchanged, compared to its average volume of 54,053. Alzamend Neuro has a 1-year low of $0.74 and a 1-year high of $11.91. The company’s fifty day moving average price is $0.95 and its 200-day moving average price is $1.36. The firm has a market cap of $5.09 million, a PE ratio of -0.75 and a beta of 0.02.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in ALZN. Vanguard Group Inc. lifted its holdings in shares of Alzamend Neuro by 6,642.3% in the third quarter. Vanguard Group Inc. now owns 4,095,775 shares of the company’s stock valued at $4,874,000 after buying an additional 4,035,028 shares during the period. BlackRock Inc. acquired a new stake in shares of Alzamend Neuro in the third quarter valued at $709,000. Geode Capital Management LLC lifted its holdings in shares of Alzamend Neuro by 7.2% in the fourth quarter. Geode Capital Management LLC now owns 563,660 shares of the company’s stock valued at $318,000 after buying an additional 37,910 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Alzamend Neuro in the second quarter valued at $56,000. Finally, Virtu Financial LLC acquired a new stake in shares of Alzamend Neuro in the fourth quarter valued at $35,000. Institutional investors and hedge funds own 49.61% of the company’s stock.
About Alzamend Neuro
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Featured Articles
- Five stocks we like better than Alzamend Neuro
- What is the Euro STOXX 50 Index?
- The Charles Schwab Company Can Hit New Highs
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- Overbought Stocks Explained: Should You Trade Them?
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.